WHO list of SARS-CoV-2 IVDS currently under assessment for Emergency Use Listing updated
IVD
Newly prequalified Active Pharmaceutical Ingredient (API)
M
Ritonavir (WHOAPI-398) manufactured by Laurus Labs Limited has been prequalified by the WHO Prequalification Unit - Medicines Team (PQT/MED) under its API prequalification procedure.
Cipla’s paediatric ritonavir tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
M
New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
Addition under section:
Baricitinib and sotrovimab invited for COVID-19
M
Baricitinib 2mg tablets and sotrovimab solution for infusion, 500 mg/8 mL (62.5 mg/mL) single use vial, invited for COVID-19.